WO2017133540A1 - Pd-1 antibodies - Google Patents
Pd-1 antibodies Download PDFInfo
- Publication number
- WO2017133540A1 WO2017133540A1 PCT/CN2017/072190 CN2017072190W WO2017133540A1 WO 2017133540 A1 WO2017133540 A1 WO 2017133540A1 CN 2017072190 W CN2017072190 W CN 2017072190W WO 2017133540 A1 WO2017133540 A1 WO 2017133540A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- sequence given
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to the field of medicine. More particularly, the present invention relates to antibodies that bind human programmed cell death 1 (PD-1) , and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
- PD-1 human programmed cell death 1
- the PD-1/human programmed cell death 1 ligand 1 (PD-L1) pathway is one such immune checkpoint. Human PD-1 is found on T cells, and the binding of PD-L1 and human programmed cell death 1 ligand 2 (PD-L2) to PD-1 inhibits T cell proliferation and cytokine production. Tumor cell production of PD-L1 and PD-L2 can therefore allow escape from T cell surveillance.
- Ahumanized IgG4 (S228P) antibody against PD-1, pembrolizumab (formerly lambrolizumab) has been shown to inhibit the binding of PD-1 to PD-L1 and PD-L2, and has been tested in various clinical trials.
- WO2008156712 and Hamid et al., N Engl J Med (2013) 369: 2 has been tested in various clinical trials.
- Certain antibodies of the present invention block the human PD-1 to PD-L1 and PD-L2 interactions in CHO cells more effectively than nivolumab and pembrolizumab. Furthermore, certain antibodies of the present invention bind murine PD-1 on CHO cells whereas nivolumab and pembrolizumab binding to murine PD-1 is not detected.
- the present invention provides an antibody that binds human PD-1 (SEQ ID NO: 1) , comprising a light chain (LC) and a heavy chain (HC) , wherein the light chain comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein the heavy chain comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 consists of the amino acid sequence:
- KASGYTFTSNYMH SEQ ID NO: 6
- HCDR2 consists of the amino acid sequence:
- HCDR3 consists of the amino acid sequence AKEGVADGYGLVDV (SEQ ID NO: 13) .
- the present invention provides an antibody that binds human PD-1 (SEQ ID NO: 1) , wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFTSYYMH (SEQ ID NO: 2) , IINPSGGSTSYAQKFQG (SEQ ID NO: 8) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- SEQ ID NO: 1 human PD-1
- LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO
- the present invention provides an antibody that binds human PD-1 (SEQ ID NO: 1) , wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFEGYYMH (SEQ ID NO: 3) , IINPEGGETSYAQKFQG (SEQ ID NO: 9) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- SEQ ID NO: 1 human PD-1
- LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID
- the present invention provides an antibody that binds human PD-1 (SEQ ID NO: 1) , wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFTAQYMH (SEQ ID NO: 4) , IINPSGGETGYAQKFQG (SEQ ID NO: 10) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- SEQ ID NO: 1 human PD-1
- LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID
- the present invention provides an antibody that binds human PD-1 (SEQ ID NO: 1) , wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFEKYYMH (SEQ ID NO: 5) , IINPDGGSTGYAQKFQG (SEQ ID NO: 12) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- SEQ ID NO: 1 human PD-1
- LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ
- the present invention provides an antibody that binds human PD-1 (SEQ ID NO: 1) , wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFTSNYMH (SEQ ID NO: 6) , IINPSEGSTGYAQKFQG (SEQ ID NO: 11) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- SEQ ID NO: 1 human PD-1
- LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO
- the present invention provides an antibody that binds human PD-1 (SEQ ID NO: 1) , wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFSAYYMH (SEQ ID NO: 7) , IINPDGGSTGYAQKFQG (SEQ ID NO: 12) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- SEQ ID NO: 1 human PD-1
- LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID
- the present invention provides an antibody, comprising a light chain (LC) and a heavy chain (HC) , wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR) , wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 22.
- LCVR light chain variable region
- HCVR heavy chain variable region
- the present invention provides an antibody, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 17.
- the present invention provides an antibody, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 18.
- the present invention provides an antibody, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 19.
- the present invention provides an antibody, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 20.
- the present invention provides an antibody, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 21.
- the present invention provides an antibody, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 22.
- the present invention provides an antibody, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: 29.
- the present invention provides an antibody, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 24.
- the present invention provides an antibody, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 25.
- the present invention provides an antibody, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 26.
- the present invention provides an antibody, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 27.
- the present invention provides an antibody, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 28.
- the present invention provides an antibody, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 29.
- the present invention provides an antibody, comprising two light chains and two heavy chains, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: 29.
- the present invention provides an antibody, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 24.
- the present invention provides an antibody, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 25.
- the present invention provides an antibody, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 26.
- the present invention provides an antibody, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 27.
- the present invention provides an antibody, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 28.
- the present invention provides an antibody, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 29.
- the present invention provides an antibody, wherein one of the heavy chains forms an inter-chain disulfide bond with one of the light chains, and the other heavy chain forms an inter-chain disulfide bond with the other light chain, and one of the heavy chains forms two inter-chain disulfide bonds with the other heavy chain.
- the present invention provides an antibody, wherein the antibody is glycosylated.
- the present invention provides an antibody that binds both human PD-1 and mouse PD-1. In a further embodiment, the present invention provides an antibody that is an antagonistic antibody and that binds both human PD-1 and mouse PD-1. In a further embodiment, the present invention provides an antibody that binds both human PD-1 and mouse PD-1with a Kd for each less than 400 pM. In a further embodiment, the present invention provides an antibody that binds both human PD-1 and mouse PD-1with a Kd for each less than 200 pM.
- the present invention provides a pharmaceutical composition, comprising an antibody of the present invention, and an acceptable carrier, diluent, or excipient.
- the present invention provides a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of an antibody of the present invention.
- the present invention provides a method of treating cancer, comprising administering to a patient in need thereof, an effective amount of an antibody of the present invention, wherein the cancer is melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, or hepatocellular carcinoma.
- these methods comprise the administration of an effective amount of the antibody of the present invention in simultaneous, separate, or sequential combination with one or more anti-tumor agents.
- anti-tumor agents include ramucirumab, necitumumab, olaratumab, galunisertib, abemaciclib, cisplatin, carboplatin, dacarbazine, liposomal doxorubicin, docetaxel, cyclophosphamide and doxorubicin, navelbine, eribulin, paclitaxel, paclitaxel protein-bound particles for injectable suspension, ixabepilone, capecitabine, FOLFOX (leucovorin, fluorouracil, and oxaliplatin) , FOLFIRI (leucovorin, fluorouracil, and irinotecan) , and cetuximab.
- these methods comprise the administration of an effective amount of the compound of the present invention in simultaneous, separate, or sequential combination with one or more immuno-oncology agents.
- immuno-oncology agents include nivolumab, ipilimumab, pidilizumab, pembrolizumab, tremelimumab, urelumab, lirilumab, atezolizumab, and durvalumab.
- the present invention provides an antibody of the present invention, for use in therapy.
- the present invention provides an antibody of the present invention, for use in the treatment of cancer.
- the present invention provides an antibody of the present invention, for use in the treatment of cancer, wherein the cancer is melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, or hepatocellular carcinoma.
- the present invention provides the antibody of the present invention for use in simultaneous, separate, or sequential combination with one or more anti-tumor agents.
- the present invention provides the antibody of the present invention for use in simultaneous, separate, or sequential combination with one or more anti-tumor agents selected from the group consisting of ramucirumab, necitumumab, olaratumab, galunisertib, abemaciclib, cisplatin, carboplatin, dacarbazine, liposomal doxorubicin, docetaxel, cyclophosphamide and doxorubicin, navelbine, eribulin, paclitaxel, paclitaxel protein-bound particles for injectable suspension, ixabepilone, capecitabine, FOLFOX (leucovorin, fluorouracil, and oxaliplatin) , FOLFIRI (leucovorin, fluorouracil, and irinotecan) , and cetuximab, in the treatment of cancer.
- one or more anti-tumor agents selected from the group consisting of ramuciruma
- the present invention provides the antibody of the present invention for use in simultaneous, separate, or sequential combination with one or more immuno-oncology agents.
- the present invention provides the antibody of the present invention for use in simultaneous, separate, or sequential combination with one or more immuno-oncology agents selected from the group consisting of nivolumab, ipilimumab, pidilizumab, pembrolizumab, tremelimumab, urelumab, lirilumab, atezolizumab, and durvalumab, in the treatment of cancer.
- the present invention provides the use of an antibody of the present invention for the manufacture of a medicament for the treatment of cancer.
- the present invention provides the use of an antibody of the present invention for the manufacture of a medicament for the treatment of cancer, wherein the cancer is melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, or hepatocellular carcinoma.
- the present invention provides the use of an antibody of the present invention in the manufacture of a medicament for the treatment of cancer wherein said medicament is to be administered simultaneously, separately, or sequentially with one or more anti-tumor agents.
- the present invention provides the use of an antibody of the present invention in the manufacture of a medicament for the treatment of cancer wherein said medicament is to be administered simultaneously, separately, or sequentially with one or more anti-tumor agents selected from the group consisting of ramucirumab, necitumumab, olaratumab, galunisertib, abemaciclib, cisplatin, carboplatin, dacarbazine, liposomal doxorubicin, docetaxel, cyclophosphamide and doxorubicin, navelbine, eribulin, paclitaxel, paclitaxel protein-bound particles for injectable suspension, ixabepilone, capecitabine, FOLFOX (leuco
- An antibody of the present invention is an engineered, non-naturally occurring polypeptide complex.
- a DNA molecule of the present invention is a non-naturally occurring DNA molecule that comprises a polynucleotide sequence encoding a polypeptide having the amino acid sequence of one of the polypeptides in an antibody of the present invention.
- An antibody of the present invention is designed to have engineered CDRs and have some portions of the antibody (all or parts of the frameworks, hinge regions, and constant regions) to be of human origin that are identical with or substantially identical (substantially human) with frameworks and constant regions derived from human genomic sequences.
- Fully human frameworks, hinge regions, and constant regions are those human germline sequences as well as sequences with naturally-occurring somatic mutations and those with engineered mutations.
- An antibody of the present invention may comprise framework, hinge, or constant regions derived from a fully human framework, hinge, or constant region containing one or more amino acid substitutions, deletions, or additions therein. Further, an antibody of the present invention is preferably substantially non-immunogenic in humans.
- the antibody of the present invention is an IgG type antibody and has “heavy” chains and “light” chains that are cross-linked via intra-and inter-chain disulfide bonds.
- Each heavy chain is comprised of an N-terminal HCVR and a heavy chain constant region ( “HCCR” ) .
- Each light chain is comprised of a LCVR and a light chain constant region ( “LCCR” ) .
- antibodies having native human Fc sequences are glycosylated in the Fc region. Typically, glycosylation occurs in the Fc region of the antibody at a highly conserved N-glycosylation site. N-glycans typically attach to asparagine.
- Antibodies may be glycosylated at other positions as well.
- the antibody of the present invention contains an Fc portion which is derived from human IgG 4 Fc region because of a reduced ability to engage Fc receptor-mediated inflammatory mechanisms or to activate complement resulting in reduced effector function.
- Certain antibodies of the present invention contain an IgG 4 -Fc portion that has a serine to proline mutation at position 228.
- the S228P mutation is a hinge mutation that prevents half-antibody formation (phenomenon of dynamic exchange of half-molecules in IgG 4 antibodies) .
- the HCVR and LCVR regions can be further subdivided into regions of hyper-variability, termed complementarity determining regions ( “CDRs” ) , interspersed with regions that are more conserved, termed framework regions ( “FR” ) .
- CDRs complementarity determining regions
- FR framework regions
- Each HCVR and LCVR is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the three CDRs of the heavy chain are referred to as “HCDR1, HCDR2, and HCDR3” and the three CDRs of the light chain are referred to as “LCDR1, LCDR2 and LCDR3” .
- the CDRs contain most of the residues which form specific interactions with the antigen.
- the Kabat CDR definition (Kabat et al., “Sequences of Proteins of Immunological Interest, ” National Institutes of Health, Bethesda, Md. (1991) ) is based upon antibody sequence variability.
- the Chothia CDR definition (Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins” , Journal of Molecular Biology, 196, 901-917 (1987) ; Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins” , Journal of Molecular Biology, 273, 927-948 (1997) ) is based on three-dimensional structures of antibodies and topologies of the CDR loops.
- the Chothia CDR definitions are identical to the Kabat CDR definitions with the exception of HCDR1 and HCDR2.
- the North CDR definition (North et al., “A New Clustering of Antibody CDR Loop Conformations” , Journal of Molecular Biology, 406, 228-256 (2011) ) is based on affinity propagation clustering with a large number of crystal structures.
- An isolated DNA encoding a HCVR region can be converted to a full-length heavy chain gene by operably linking the HCVR-encoding DNA to another DNA molecule encoding heavy chain constant regions.
- the sequences of human, as well as other mammalian, heavy chain constant region genes are known in the art. DNA fragments encompassing these regions can be obtained e.g., by standard PCR amplification.
- An isolated DNA encoding a LCVR region may be converted to a full-length light chain gene by operably linking the LCVR-encoding DNA to another DNA molecule encoding a light chain constant region.
- the sequences of human, as well as other mammalian, light chain constant region genes are known in the art. DNA fragments encompassing these regions can be obtained by standard PCR amplification.
- the light chain constant region can be a kappa or lambda constant region.
- the polynucleotides of the present invention will be expressed in a host cell after the sequences have been operably linked to an expression control sequence.
- the expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline, neomycin, and dihydrofolate reductase, to permit detection of those cells transformed with the desired DNA sequences.
- the antibody of the present invention may readily be produced in mammalian cells such as CHO, NS0, HEK293 or COS cells.
- the host cells are cultured using techniques well known in the art.
- the vectors containing the polynucleotide sequences of interest can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host.
- the antibody, or the nucleic acids encoding the same is provided in isolated form.
- isolated refers to a protein, peptide, or nucleic acid which is free or substantially free from any other macromolecular species found in a cellular environment. “Substantially free” as used herein means the protein, peptide, or nucleic acid of interest comprises more than 80% (on a molar basis) of the macromolecular species present, preferably more than 90%, and more preferably more than 95%.
- the antibody of the present invention may be administered by parenteral routes (e.g., subcutaneous and intravenous) .
- An antibody of the present invention may be administered to a patient alone with pharmaceutically acceptable carriers, diluents, or excipients in single or multiple doses.
- Pharmaceutical compositions of the present invention can be prepared by methods well known in the art (e.g., Remington: The Science and Practice of Pharmacy, 19 th ed. (1995) , A. Gennaro et al., Mack Publishing Co. ) and comprise an antibody, as disclosed herein, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
- treating refers to slowing, interrupting, arresting, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease.
- Binds as used herein in reference to the affinity of an antibody for human PD-1 is intended to mean, unless indicated otherwise, a K D of less than about 1x10-6 M, preferably, less than about 1 x 10-9 M as determined by common methods known in the art, including by use of MSD essentially as described herein.
- the term “high affinity” refers to a K D of less than about 150pM for human PD-1 as determined by MSD.
- the K D values are established by binding kinetics as described in “Binding kinetics and affinity” in the Assays section.
- Effective amount means the amount of an antibody of the present invention or pharmaceutical composition comprising an antibody of the present invention that will elicit the biological or medical response of or desired therapeutic effect on a tissue, system, animal, mammal or human that is being sought by the researcher, medical doctor, or other clinician.
- An effective amount of the antibody may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody to elicit a desired response in the individual.
- An effective amount is also one in which any toxic or detrimental effect of the antibody is outweighed by the therapeutically beneficial effects.
- polypeptides of the variable regions of the heavy chain and light chain, the complete heavy chain and light chain amino acid sequences of Antibody A-Antibody F, and the nucleotide sequences encoding the same are listed below in the section entitled “Amino Acid and Nucleotide Sequences. ”
- SEQ ID NOs for the light chain, heavy chain, light chain variable region, and heavy chain variable region of Antibody A-Antibody F are shown in Table 1.
- the antibodies of the present invention including, but not limited to, Antibody A -Antibody F can be made and purified essentially as follows.
- An appropriate host cell such as HEK 293 or CHO, can be either transiently or stably transfected with an expression system for secreting antibodies using an optimal predetermined HC: LC vector ratio or a single vector system encoding both HC and LC. Clarified media, into which the antibody has been secreted, may be purified using any of many commonly-used techniques.
- the medium may be conveniently applied to a MabSelect column (GE Healthcare) , or KappaSelect column (GE Healthcare) for Fab fragment, that has been equilibrated with a compatible buffer, such as phosphate buffered saline (pH 7.4) .
- a compatible buffer such as phosphate buffered saline (pH 7.4) .
- the column may be washed to remove nonspecific binding components.
- the bound antibody may be eluted, for example, by pH gradient (such as 20 mM Tris buffer pH 7 to 10 mM sodium citrate buffer pH 3.0, or phosphate buffered saline pH 7.4 to 100 mM glycine buffer pH 3.0) .
- Antibody fractions may be detected, such as by SDS-PAGE, and then may be pooled.
- the antibody may be concentrated and/or sterile filtered using common techniques. Soluble aggregate and multimers may be effectively removed by common techniques, including size exclusion, hydrophobic interaction, ion exchange, multimodal, or hydroxyapatite chromatography. The purity of the antibody after these chromatography steps is greater than 95%.
- the product may be immediately frozen at-70°C or may be lyophilized.
- K D The kinetics and equilibrium dissociation constant (K D ) for human PD-1 is determined for antibodies of the present invention using MSD, and bio-layer interferometry (ForteBio) assay methods.
- nivolumab is a human IgG4 PD-1 antibody transiently expressed in 293 HEK cells that utilizes the heavy chain and light chain sequences from Proposed INN: List 107 (CAS #946414-94-4) .
- pembrolizumab is a human IgG4 PD-1 antibody transiently expressed in 293 HEK cells that utilizes the heavy chain and light chain sequences from Proposed INN: List 72.
- Plates are then washed 3x with wash buffer (PBSF+0.05%Tween 20) .
- SET samples are applied and incubated on the plates for 150s with shaking at 700 rpm followed by one wash.
- Antigen captured on a plate is detected with 250 ng/mL sulfotag-labeled streptavidin in PBSF by incubation on the plate for 3 min.
- the plates are washed three times with wash buffer and are then read on the MSD Sector Imager 2400 instrument using 1x Read Buffer T with surfactant.
- the percent free antigen is plotted as a function of titrated antibody in Prism and fit to a quadratic equation to extract the KD.
- liquid handling robots are used throughout MSD-SET experiments, including for SET sample preparation.
- Antibody C and Antibody E in an IgG1 format and expressed in yeast, bind human PD-1 with a K D of 120 pM and 91 pM, respectively.
- Pembrolizumab and nivolumab bind PD-1 with a K D of 130 pM and 640 pM respectively.
- Avidity measurements for Antibody C and Antibody E result in a K D of approximately 9 pM and 22 pM, respectively, to human PD-1.
- Pembrolizumab and nivolumab bind human PD-1 with a K D of approximately 3 pM and 5 pM respectively.
- Antibody C and Antibody E in an IgG1 format and expressed in yeast, bind murine PD-1 with a K D of 1900 pM and 1100 pM, respectively.
- Avidity measurements for Antibody C and Antibody E result in a K D of approximately 130 pM and 330 pM, respectively, to murine PD-1.
- Table 1 Binding by MSD of antibodies of the invention in IgG1 format (P.F.: poor fit; N.D.: none detected)
- ForteBio affinity measurements were performed generally as previously described (Estep, P., et al., High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs, 2013. 5 (2) : p. 270-8. ) . Briefly, ForteBio affinity measurements were performed by loading IgGs online onto AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 min and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded IgGs were exposed to 100 nM antigen for 5 min, afterwards they were transferred to assaybuffer for 5 min for off-rate measurement. Kinetics was analyzed using the 1: 1 binding model.
- Antibody C and Antibody E in an IgG1 format and expressed in yeast, bind human PD-1_Fc with a K D similar to nivolumab and pembrolizumab when PD-1_Fc was on the sensor tip.
- Antibody C and Antibody E in an IgG1 format and expressed in yeast, bind human PD-1_Fc with a K D similarly to nivolumab and pembrolizumab.
- Antibody C and Antibody E in an IgG1 format and expressed in yeast, bind cyno PD-1_Fc with a similarK D to nivolumab and pembrolizumab.
- Antibody C and Antibody E in an IgG1 format and expressed in yeast, bind murine PD-1_Fc whereas no binding was detected with nivolumab and pembrolizumab.
- the binding of an antibody of the present invention to human PD-1 may be measured in a flow cytometry assay.
- CHO cells (0.2 x 10 6 ) are incubated with the experimental antibody from 100 nM titrated 14x by a factor of 2 to the lowest concentration of 6.1 pM for 30 min in PBS 1%BSA on ice. Cells are then washed 3x, and are incubated with a secondary antibody (PE-labelled, at final concentration of 5 ⁇ g/ml) inPBS 1%BSA for 30 min on ice (protected from light) . Cells are washed 3x and analyzed via flow cytometry. Flow cytometryis performed on an Accuri C6 system (BD Biosciences) and MFIs are calculated on the C6 software. EC50s are calculated on Graphpad software.
- Antibody A, B, C, D, E, and F, in an IgG1 format and expressed in yeast bind to murine PD-1 in a dose dependent manner with an EC50 of 11.01 nM, 6.135 nM, 2.884 nM, 9.259 nM, and 5.044 nM, and 5.855 nM, respectively, whereas no binding was detected for nivolumab or pembrolizumab.
- the ability of an antibody of the present invention to block binding of human PD-1 to PD-L1 and PD-L2 may be measured by flow cytometry.
- CHO cells 0.2 x 10 6 are incubated with the experimental antibody (100 nM) for 30 min in PBS 1%BSA on ice. Cells are then washed 3X, and are incubated with PD-L2 linked with NHS-FIuorescein (Promega) in PBS 1%BSA for 30 min on ice (protected from light) . Cells are washed 3x and analyzed via flow cytometry. Flow cytometry is performed on an Accuri C6 system (BD Biosciences) and MFIs are calculated on the C6 software. EC50s are calculated on Graphpad software.
- Antibody C and Antibody E blocked human PD-L2-FITC binding, resulting in an MFI of 30,123.4 and 38,682.1, respectively, as compared to control IgG which resulted in an MFI of 182,959.1.
- Pembrolizumab and nivolumab resulted in MFI’s of 46,245.9 and 54,509.8 respectively.
- Test Sample MFI (PD-L2-FITC) Cells only 33,449.7 No IgG 199,716.0 IgG Control 182,959.1 Nivolumab 54,509.8 Pembrolizumab 46,245.9 Antibody A 90,866.5 Antibody C 30,123.4 Antibody E 38,682.1
- the blocking of PD-1 signals by antibodies of the present invention may be evaluated by measuring the release of inhibitory signals during T cell activation.
- 2 x 10 6 PBMC are plated per well in a 6 well tissue culture plate or T25 tissue culture flask in complete T cell media. Cells are incubated for 2-3 hours, to allow for adherence of monocytes. If adherence is insufficient, serum free media is used. Unattached cells are removed by gently swirling the flask with fresh media 3X.
- Immature myeloid DCs are generated by culturing monocytes (1 x 10 6 cells/ml) from PBMC in X-VIVO 15 media containing 1%AB serum, 10 mM HEPES, 50 ⁇ M ⁇ -Me, IL-4 (1000 U/ml) and GM-CSF (1000 U/ml) , or 25-50 ng/ml of each. After 2 days fresh medium supplemented with IL-4 and GM-CSF is added.
- cells are either frozen or maturation is induced by adding a stimulation cocktail containing rTNFa (1000U/ml) , IL-1b (5 ng/ml) , IL-6 (10ng/ml) and 1 ⁇ M PGE 2 for 2 days at a cell density of 3 x 10 5 cells/ml.
- rTNFa 1000U/ml
- IL-1b 5 ng/ml
- IL-6 10ng/ml
- 1 ⁇ M PGE 2 for 2 days at a cell density of 3 x 10 5 cells/ml.
- T cell Isolation is performed as per manufacturer’s instructions in the Untouched CD4+T cell isolation kit (Invitrogen) .
- a magnet fitted with a 1.5 ml tube rack is used to remove unwanted magnetic beads (QIAGEN) .
- 100,000-200,000 isolated T cells are mixed with 10,000-20,000 allogeneic moDCs in a total volume of 200 ⁇ l in 96-round bottom tissue culture plates for 4-5 days at 37°C.
- T cells are stimulated using anti-CD3/CD28 DynaBeads at a ratio of3: 1 (cells: beads) as a positive control; beads are prepared as per the manufacturer’s instructions.
- Test antibodies are added at the beginning of the MLR and incubated throughout the culture period. Detection of IL-2 and IFN- ⁇ is carried out as per manufacturer’s instructions (eBioscience) .
- OD measurements are determined on a Multiskan FC system (Thermo) .
- Antibody C and Antibody E increase IL-2 and IFNg secretion by activated T cells in the mixed lymphocyte reaction with equivalent potency as compared with nivolumab and pembrolizumab.
- the antibodies of the present invention can be measured for in vivo immunomodulatory activity with the MC38 in vivo tumor mode.
- RMP1-14 group is given a dose of 10 mg/kg.
- Compound C-2.5, Compound C-5, and Compound C-10 groups are given 2.5 mg/kg, 5 mg/kg and 10 mg/kg of 11430 respectively (Compound C S228P IgG4 produced in HEK293 cells) .
- RMP1-14 group had a relative tumor inhibition value of 55.03%, with Compound C-2.5, Compound C-5, and Compound C-10 groups with relative tumor inhibition values of 69.70%, 76.53%, and 81.04%, respectively, showing a dose-dependent manner of Compound C on tumor weight.
- Compound C has significant anti-tumor efficacy in tumor-bearing mice, and has better effect than the positive control clone RMP1-14.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Test Sample | MFI (PD-L2-FITC) |
Cells only | 33,449.7 |
No IgG | 199,716.0 |
IgG Control | 182,959.1 |
Nivolumab | 54,509.8 |
Pembrolizumab | 46,245.9 |
Antibody A | 90,866.5 |
Antibody C | 30,123.4 |
Antibody E | 38,682.1 |
Claims (39)
- An antibody that binds human PD-1 (SEQ ID NO: 1) , comprising a light chain (LC) and a heavy chain (HC) , wherein the light chain comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein the heavy chain comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 consists of the amino acid sequence:a. KASGYTFTSYYMH (SEQ ID NO: 2) ,b. KASGYTFEGYYMH (SEQ ID NO: 3) ,c. KASGYTFTAQYMH (SEQ ID NO: 4) ,d. KASGYTFEKYYMH (SEQ ID NO: 5) ,e. KASGYTFTSNYMH (SEQ ID NO: 6) , orf. KASGYTFSAYYMH (SEQ ID NO: 7) ;wherein HCDR2 consists of the amino acid sequence:a. IINPSGGSTSYAQKFQG (SEQ ID NO: 8) ,b. IINPEGGETSYAQKFQG (SEQ ID NO: 9) ,c. IINPSGGETGYAQKFQG (SEQ ID NO: 10) ,d. IINPSEGSTGYAQKFQG (SEQ ID NO: 11) , ore. IINPDGGSTGYAQKFQG (SEQ ID NO: 12) ;and wherein HCDR3 consists of the amino acid sequence AKEGVADGYGLVDV (SEQ ID NO: 13) .
- The antibody of Claim 1, wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFTSYYMH (SEQ ID NO: 2) , IINPSGGSTSYAQKFQG (SEQ ID NO: 8) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- The antibody of Claim 1, wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFEGYYMH (SEQ ID NO: 3) , IINPEGGETSYAQKFQG (SEQ ID NO: 9) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- The antibody of Claim 1, wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFTAQYMH (SEQ ID NO: 4) , IINPSGGETGYAQKFQG (SEQ ID NO: 10) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- The antibody of Claim 1, wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFEKYYMH (SEQ ID NO: 5) , IINPDGGSTGYAQKFQG (SEQ ID NO: 12) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- The antibody of Claim 1, wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFTSNYMH (SEQ ID NO: 6) , IINPSEGSTGYAQKFQG (SEQ ID NO: 11) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- The antibody of Claim 1, wherein LCDR1, LCDR2, and LCDR3 consist of the amino acid sequences RASQSVSSYLA (SEQ ID NO: 14) , YDASKRAT (SEQ ID NO: 15) , and DQRNNWPLT (SEQ ID NO: 16) , respectively, and wherein HCDR1, HCDR2, and HCDR3 consist of the amino acid sequences KASGYTFSAYYMH (SEQ ID NO: 7) , IINPDGGSTGYAQKFQG (SEQ ID NO: 12) , and AKEGVADGYGLVDV (SEQ ID NO: 13) , respectively.
- An antibody, comprising a light chain (LC) and a heavy chain (HC) , wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR) , wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 22.
- The antibody of Claim 8, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 17.
- The antibody of Claim 8, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 18.
- The antibody of Claim 8, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 19.
- The antibody of Claim 8, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 20.
- The antibody of Claim 8, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 21.
- The antibody of Claim 8, wherein the LCVR has the amino acid sequence given in SEQ ID NO: 23, and the HCVR has the amino acid sequence given in SEQ ID NO: 22.
- The antibody of Claim 8, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: 29.
- The antibody of Claim 15, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 24.
- The antibody of Claim 15, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 25.
- The antibody of Claim 15, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 26.
- The antibody of Claim 15, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 27.
- The antibody of Claim 15, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 28.
- The antibody of Claim 15, wherein the LC has the amino acid sequence given in SEQ ID NO: 30, and the HC has the amino acid sequence given in SEQ ID NO: 29.
- The antibody of Claim 15, comprising two light chains and two heavy chains, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: 29.
- The antibody of Claim 22, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 24.
- The antibody of Claim 22, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 25.
- The antibody of Claim 22, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 26.
- The antibody of Claim 22, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 27.
- The antibody of Claim 22, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 28.
- The antibody of Claim 22, wherein each light chain has the amino acid sequence given in SEQ ID NO: 30, and each heavy chain has the amino acid sequence given in SEQ ID NO: 29.
- The antibody of any one of Claims 22-28, wherein one of the heavy chains forms an inter-chain disulfide bond with one of the light chains, and the other heavy chain forms an inter-chain disulfide bond with the other light chain, and one of the heavy chains forms two inter-chain disulfide bonds with the other heavy chain.
- The antibody of any one of Claims 1-29, wherein the antibody is glycosylated.
- A pharmaceutical composition, comprising the antibody of any one of Claims 1-30, and an acceptable carrier, diluent, or excipient.
- A method of treating cancer, comprising administering to apatient in need thereof, an effective amount of the antibody of any one of Claims 1-30.
- The method of Claim 32, wherein the cancer is melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, or hepatocellular carcinoma.
- The method of Claim 32 or 33, further comprising administering simultaneously, separately, or sequentially one or more anti-tumor agents.
- The antibody of any one of Claims 1-30, for use in therapy.
- The antibody of any one of Claims 1-30, for use in the treatment of cancer.
- The antibody for use of Claim 36, wherein the cancer is melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, or hepatocellular carcinoma.
- The antibody of any one of Claims 1-30 for use in simultaneous, separate, or sequential combination with one or more anti-tumor agents, in the treatment of cancer.
- The combination for use of Claim 38, wherein the cancer is melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, or hepatocellular carcinoma.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018558472A JP6533630B2 (en) | 2016-02-02 | 2017-01-23 | PD-1 antibody |
US16/073,942 US10913801B2 (en) | 2016-02-02 | 2017-01-23 | PD-1 antibodies |
CN201780009384.5A CN108779177B (en) | 2016-02-02 | 2017-01-23 | PD-1 antibodies |
EP17746860.0A EP3411410B1 (en) | 2016-02-02 | 2017-01-23 | Pd-1 antibodies |
ES17746860T ES2876407T3 (en) | 2016-02-02 | 2017-01-23 | Anti-Pd-1 antibodies |
DK17746860.0T DK3411410T3 (en) | 2016-02-02 | 2017-01-23 | PD-1 ANTIBODIES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2016/073169 WO2017132827A1 (en) | 2016-02-02 | 2016-02-02 | Pd-1 antibodies |
CNPCT/CN2016/073169 | 2016-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017133540A1 true WO2017133540A1 (en) | 2017-08-10 |
Family
ID=59500510
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/073169 WO2017132827A1 (en) | 2016-02-02 | 2016-02-02 | Pd-1 antibodies |
PCT/CN2017/072190 WO2017133540A1 (en) | 2016-02-02 | 2017-01-23 | Pd-1 antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/073169 WO2017132827A1 (en) | 2016-02-02 | 2016-02-02 | Pd-1 antibodies |
Country Status (7)
Country | Link |
---|---|
US (1) | US10913801B2 (en) |
EP (1) | EP3411410B1 (en) |
JP (1) | JP6533630B2 (en) |
CN (1) | CN108779177B (en) |
DK (1) | DK3411410T3 (en) |
ES (1) | ES2876407T3 (en) |
WO (2) | WO2017132827A1 (en) |
Cited By (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018081621A1 (en) | 2016-10-28 | 2018-05-03 | Bristol-Myers Squibb Company | Methods of treating urothelial carcinoma using an anti-pd-1 antibody |
WO2018085555A1 (en) | 2016-11-03 | 2018-05-11 | Bristol-Myers Squibb Company | Activatable anti-ctla-4 antibodies and uses thereof |
WO2018152396A1 (en) | 2017-02-17 | 2018-08-23 | Innate Tumor Immunity, Inc. | Substituted imidazo-quinolines as nlrp3 modulators |
WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2018187613A2 (en) | 2017-04-07 | 2018-10-11 | Bristol-Myers Squibb Company | Anti-icos agonist antibodies and uses thereof |
WO2018223040A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-pd-1 antibody |
WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
WO2018222711A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
WO2018222718A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
WO2019014402A1 (en) | 2017-07-14 | 2019-01-17 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019090330A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Methods of treating a tumor |
US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
WO2019129137A1 (en) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anti-lag-3 antibody and uses thereof |
EP3383915A4 (en) * | 2016-10-15 | 2019-07-24 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
WO2019144126A1 (en) | 2018-01-22 | 2019-07-25 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
WO2019144098A1 (en) | 2018-01-22 | 2019-07-25 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
WO2019143607A1 (en) | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019195452A1 (en) | 2018-04-04 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
WO2019209896A1 (en) | 2018-04-25 | 2019-10-31 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2019210848A1 (en) * | 2018-05-03 | 2019-11-07 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom |
WO2019217457A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
WO2020023707A1 (en) | 2018-07-26 | 2020-01-30 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
WO2020020281A1 (en) | 2018-07-25 | 2020-01-30 | 信达生物制药(苏州)有限公司 | Anti-tigit antibody and uses thereof |
WO2020037092A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
WO2020037091A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
WO2020037094A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
WO2020076799A1 (en) | 2018-10-09 | 2020-04-16 | Bristol-Myers Squibb Company | Anti-mertk antibodies for treating cancer |
WO2020081928A1 (en) | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
WO2020086724A1 (en) | 2018-10-23 | 2020-04-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
WO2020117849A1 (en) | 2018-12-04 | 2020-06-11 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
WO2020127373A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
WO2020136133A1 (en) | 2018-12-23 | 2020-07-02 | F. Hoffmann-La Roche Ag | Tumor classification based on predicted tumor mutational burden |
WO2020150115A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2020150113A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer |
WO2020150116A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2020150114A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Heterocyclic nlrp3 modulators, for use in the treatment of cancer |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
WO2020198676A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020198672A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
WO2021006199A1 (en) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
WO2021025140A1 (en) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | Dual-specific protein |
WO2021025177A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
WO2021062018A1 (en) | 2019-09-25 | 2021-04-01 | Bristol-Myers Squibb Company | Composite biomarker for cancer therapy |
WO2021092044A1 (en) | 2019-11-05 | 2021-05-14 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
WO2021092380A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
WO2021127554A1 (en) | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
WO2021142203A1 (en) | 2020-01-10 | 2021-07-15 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2021152005A1 (en) | 2020-01-28 | 2021-08-05 | Universite De Strasbourg | Antisense oligonucleotide targeting linc00518 for treating melanoma |
WO2021152548A1 (en) | 2020-01-30 | 2021-08-05 | Benitah Salvador Aznar | Combination therapy for treatment of cancer and cancer metastasis |
WO2021158938A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
WO2021176424A1 (en) | 2020-03-06 | 2021-09-10 | Ona Therapeutics, S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2021178807A1 (en) | 2020-03-06 | 2021-09-10 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
WO2021194942A1 (en) | 2020-03-23 | 2021-09-30 | Bristol-Myers Squibb Company | Anti-ccr8 antibodies for treating cancer |
WO2021224438A1 (en) | 2020-05-07 | 2021-11-11 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022047189A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
WO2022076318A1 (en) | 2020-10-05 | 2022-04-14 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
WO2022074107A1 (en) | 2020-10-09 | 2022-04-14 | Worldwide Innovative Network | Novel prediction method and gene signatures for the treatment of cancer |
WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022094567A1 (en) | 2020-10-28 | 2022-05-05 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
WO2022108931A2 (en) | 2020-11-17 | 2022-05-27 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022129512A1 (en) | 2020-12-17 | 2022-06-23 | Ose Immunotherapeutics | Bifunctional anti-pd1/il-7 molecules |
WO2022136266A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022136257A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
WO2022203090A1 (en) | 2021-03-25 | 2022-09-29 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023007472A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2023052531A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
WO2023061930A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023083868A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
US11732044B2 (en) * | 2017-12-27 | 2023-08-22 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-LAG-3 antibody and use thereof |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2023196964A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
WO2024023740A1 (en) | 2022-07-27 | 2024-02-01 | Astrazeneca Ab | Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
US11939381B2 (en) | 2018-07-19 | 2024-03-26 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
US11993653B2 (en) | 2016-12-07 | 2024-05-28 | Agenus Inc. | Antibodies and methods of use thereof |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
WO2024116140A1 (en) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
WO2024137776A1 (en) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
WO2024150177A1 (en) | 2023-01-11 | 2024-07-18 | Advesya | Treatment methods for solid tumors |
EP4204454A4 (en) * | 2020-08-31 | 2024-07-24 | Biosion Inc | Pd-1 binding antibodies and uses thereof |
WO2024175699A1 (en) | 2023-02-23 | 2024-08-29 | Imcheck Therapeutics | Combination of btn3a activating antibody and immune checkpoint inhibitors |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913303XA (en) | 2015-07-13 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
CN108314734B (en) * | 2018-01-31 | 2021-11-05 | 中国药科大学 | anti-PD-1 monoclonal antibody and application thereof |
TWI793395B (en) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥(蘇州)有限公司 | Bispecific antibodies that bind to pd-l1 and ox40 |
AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
JP2022554270A (en) * | 2019-11-05 | 2022-12-28 | ジョンス セラピューティクス, インコーポレイテッド | Methods of treating cancer with anti-PD-1 antibodies |
TW202128171A (en) * | 2020-01-13 | 2021-08-01 | 大陸商信達生物製藥(蘇州)有限公司 | Pharmaceutical combination of anti-pd-1 antibody and quinazoline derivaticves and use thereof, and methods using the same |
WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
TW202327595A (en) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | Combinations of azalactam compounds for the treatment of cancer |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
CN103242448A (en) * | 2013-05-27 | 2013-08-14 | 郑州大学 | Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof |
US8557777B2 (en) * | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
CN104250302A (en) * | 2013-06-26 | 2014-12-31 | 上海君实生物医药科技有限公司 | Anti-PD-1 antibody and its application |
CN105175544A (en) * | 2015-10-20 | 2015-12-23 | 安徽瀚海博兴生物技术有限公司 | Anti-PD-1 humanized monoclonal antibody and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG2014011365A (en) | 2008-09-19 | 2014-05-29 | Hoffmann La Roche | Novel antibody formulation |
TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
-
2016
- 2016-02-02 WO PCT/CN2016/073169 patent/WO2017132827A1/en active Application Filing
-
2017
- 2017-01-23 DK DK17746860.0T patent/DK3411410T3/en active
- 2017-01-23 US US16/073,942 patent/US10913801B2/en active Active
- 2017-01-23 EP EP17746860.0A patent/EP3411410B1/en active Active
- 2017-01-23 WO PCT/CN2017/072190 patent/WO2017133540A1/en active Application Filing
- 2017-01-23 CN CN201780009384.5A patent/CN108779177B/en active Active
- 2017-01-23 JP JP2018558472A patent/JP6533630B2/en active Active
- 2017-01-23 ES ES17746860T patent/ES2876407T3/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
US8557777B2 (en) * | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
CN103242448A (en) * | 2013-05-27 | 2013-08-14 | 郑州大学 | Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof |
CN104250302A (en) * | 2013-06-26 | 2014-12-31 | 上海君实生物医药科技有限公司 | Anti-PD-1 antibody and its application |
WO2014206107A1 (en) | 2013-06-26 | 2014-12-31 | 上海君实生物医药科技有限公司 | Anti-pd-1 antibody and use thereof |
CN105175544A (en) * | 2015-10-20 | 2015-12-23 | 安徽瀚海博兴生物技术有限公司 | Anti-PD-1 humanized monoclonal antibody and application thereof |
Non-Patent Citations (17)
Title |
---|
A. GENNARO ET AL.: "Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO. |
AL-LAZIKANI ET AL.: "Standard conformations for the canonical structures of immunoglobulins", JOURNAL OF MOLECULAR BIOLOGY, vol. 273, 1997, pages 927 - 948, XP004461383, DOI: 10.1006/jmbi.1997.1354 |
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 946414-94-4 |
CHOTHIA ET AL.: "Canonical structures for the hypervariable regions of immunoglobulins", JOURNAL OF MOLECULAR BIOLOGY, vol. 196, 1987, pages 901 - 917, XP024010426, DOI: 10.1016/0022-2836(87)90412-8 |
DEUTSCHER, METHODS IN ENZYMOLOGY, vol. 182, 1990, pages 83 - 89 |
ESTEP, P. ET AL.: "High throughput solution-based measurement of antibody-antigen affinity and epitope binning", MABS, vol. 5, no. 2, 2013, pages 270 - 8, XP055105281, DOI: 10.4161/mabs.23049 |
HAMID ET AL., N ENGL J MED, vol. 369, 2013, pages 2 |
IKEBUCHI R. ET AL., MICROBIOLOGY AND IMMUNOLOGY, vol. 54, 2010, pages 291 - 298 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH |
LI D. ET AL., MABS, vol. 9, no. 4, 2017, pages 628 - 637 |
NORTH ET AL.: "A New Clustering of Antibody CDR Loop Conformations", JOURNAL OF MOLECULAR BIOLOGY, vol. 406, 2011, pages 228 - 256, XP028129711, DOI: 10.1016/j.jmb.2010.10.030 |
RIZVI, NA ET AL.: "Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small- cell lung cancer (CheckMate 063): a phase 2, single-arm trial", LANCET ONCOLOGY, vol. 3, no. 16, 31 March 2015 (2015-03-31), pages 257 - 265, XP055404123, ISSN: 1470-2045 * |
SCOPES: "Protein Purification: Principles and Practice", 1994, SPRINGER |
See also references of EP3411410A4 |
WANG C. ET AL., CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 9, 2014 |
WANG ET AL., CANCER IMMUNOL RES, vol. 2, no. 9, 2014, pages 846 |
ZHIYU HUANG ET AL.: "Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer", CHINESE JOURNAL OF LUNG CANCER, vol. 11, no. 18, 30 November 2015 (2015-11-30), pages 706 - 713, XP055455195, ISSN: 1009-3419 * |
Cited By (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10450373B2 (en) | 2015-09-01 | 2019-10-22 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
US11345755B2 (en) | 2015-09-01 | 2022-05-31 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
EP3383915A4 (en) * | 2016-10-15 | 2019-07-24 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
WO2018081621A1 (en) | 2016-10-28 | 2018-05-03 | Bristol-Myers Squibb Company | Methods of treating urothelial carcinoma using an anti-pd-1 antibody |
WO2018085555A1 (en) | 2016-11-03 | 2018-05-11 | Bristol-Myers Squibb Company | Activatable anti-ctla-4 antibodies and uses thereof |
US11117968B2 (en) | 2016-11-03 | 2021-09-14 | Bristol-Myers Squibb Company | Activatable anti-CTLA-4 antibodies and uses thereof |
US11993653B2 (en) | 2016-12-07 | 2024-05-28 | Agenus Inc. | Antibodies and methods of use thereof |
EP3753938A1 (en) | 2017-02-17 | 2020-12-23 | Innate Tumor Immunity, Inc. | Substituted imidazo-quinolines as nlrp3 modulators |
WO2018152396A1 (en) | 2017-02-17 | 2018-08-23 | Innate Tumor Immunity, Inc. | Substituted imidazo-quinolines as nlrp3 modulators |
WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2018187613A2 (en) | 2017-04-07 | 2018-10-11 | Bristol-Myers Squibb Company | Anti-icos agonist antibodies and uses thereof |
WO2018222711A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
EP4306542A2 (en) | 2017-05-30 | 2024-01-17 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
US11723975B2 (en) | 2017-05-30 | 2023-08-15 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
EP4245375A2 (en) | 2017-05-30 | 2023-09-20 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
US12049503B2 (en) | 2017-05-30 | 2024-07-30 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
US11807686B2 (en) | 2017-05-30 | 2023-11-07 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
WO2018222718A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
WO2018223040A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-pd-1 antibody |
US11566073B2 (en) | 2017-06-01 | 2023-01-31 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-PD-1 antibody |
WO2019014402A1 (en) | 2017-07-14 | 2019-01-17 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
US11919957B2 (en) | 2017-10-15 | 2024-03-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019090330A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2019129137A1 (en) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anti-lag-3 antibody and uses thereof |
US11732044B2 (en) * | 2017-12-27 | 2023-08-22 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-LAG-3 antibody and use thereof |
WO2019143607A1 (en) | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
WO2019144126A1 (en) | 2018-01-22 | 2019-07-25 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
WO2019144098A1 (en) | 2018-01-22 | 2019-07-25 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019195452A1 (en) | 2018-04-04 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
EP4353235A2 (en) | 2018-04-25 | 2024-04-17 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2019209896A1 (en) | 2018-04-25 | 2019-10-31 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
US12060425B2 (en) | 2018-05-03 | 2024-08-13 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
WO2019210848A1 (en) * | 2018-05-03 | 2019-11-07 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom |
WO2019217457A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
US11939381B2 (en) | 2018-07-19 | 2024-03-26 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
WO2020020281A1 (en) | 2018-07-25 | 2020-01-30 | 信达生物制药(苏州)有限公司 | Anti-tigit antibody and uses thereof |
US11370837B2 (en) | 2018-07-25 | 2022-06-28 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-TIGIT antibody and use thereof |
WO2020023707A1 (en) | 2018-07-26 | 2020-01-30 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
WO2020037094A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
WO2020037091A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
WO2020037092A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
WO2020076799A1 (en) | 2018-10-09 | 2020-04-16 | Bristol-Myers Squibb Company | Anti-mertk antibodies for treating cancer |
WO2020081928A1 (en) | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
WO2020086724A1 (en) | 2018-10-23 | 2020-04-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
WO2020117849A1 (en) | 2018-12-04 | 2020-06-11 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
WO2020127373A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
WO2020136133A1 (en) | 2018-12-23 | 2020-07-02 | F. Hoffmann-La Roche Ag | Tumor classification based on predicted tumor mutational burden |
WO2020150114A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Heterocyclic nlrp3 modulators, for use in the treatment of cancer |
WO2020150115A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2020150113A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer |
WO2020150116A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
WO2020198676A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020198672A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
WO2021006199A1 (en) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
WO2021025177A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021025140A1 (en) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | Dual-specific protein |
WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
WO2021062018A1 (en) | 2019-09-25 | 2021-04-01 | Bristol-Myers Squibb Company | Composite biomarker for cancer therapy |
WO2021092044A1 (en) | 2019-11-05 | 2021-05-14 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092380A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
WO2021127554A1 (en) | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
WO2021142203A1 (en) | 2020-01-10 | 2021-07-15 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2021152005A1 (en) | 2020-01-28 | 2021-08-05 | Universite De Strasbourg | Antisense oligonucleotide targeting linc00518 for treating melanoma |
WO2021152548A1 (en) | 2020-01-30 | 2021-08-05 | Benitah Salvador Aznar | Combination therapy for treatment of cancer and cancer metastasis |
WO2021158938A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
WO2021178807A1 (en) | 2020-03-06 | 2021-09-10 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
WO2021176424A1 (en) | 2020-03-06 | 2021-09-10 | Ona Therapeutics, S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2021194942A1 (en) | 2020-03-23 | 2021-09-30 | Bristol-Myers Squibb Company | Anti-ccr8 antibodies for treating cancer |
WO2021224438A1 (en) | 2020-05-07 | 2021-11-11 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
WO2022047189A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
EP4204454A4 (en) * | 2020-08-31 | 2024-07-24 | Biosion Inc | Pd-1 binding antibodies and uses thereof |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022076318A1 (en) | 2020-10-05 | 2022-04-14 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
WO2022074107A1 (en) | 2020-10-09 | 2022-04-14 | Worldwide Innovative Network | Novel prediction method and gene signatures for the treatment of cancer |
WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022094567A1 (en) | 2020-10-28 | 2022-05-05 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
WO2022108931A2 (en) | 2020-11-17 | 2022-05-27 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022129512A1 (en) | 2020-12-17 | 2022-06-23 | Ose Immunotherapeutics | Bifunctional anti-pd1/il-7 molecules |
WO2022136266A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022136257A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022136255A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
WO2022203090A1 (en) | 2021-03-25 | 2022-09-29 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023007472A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023052531A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
WO2023061930A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023083868A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2023196964A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024017510A1 (en) | 2022-07-21 | 2024-01-25 | Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
WO2024023740A1 (en) | 2022-07-27 | 2024-02-01 | Astrazeneca Ab | Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
WO2024116140A1 (en) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
WO2024137776A1 (en) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
WO2024150177A1 (en) | 2023-01-11 | 2024-07-18 | Advesya | Treatment methods for solid tumors |
WO2024175699A1 (en) | 2023-02-23 | 2024-08-29 | Imcheck Therapeutics | Combination of btn3a activating antibody and immune checkpoint inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP3411410A1 (en) | 2018-12-12 |
CN108779177B (en) | 2021-09-24 |
EP3411410A4 (en) | 2019-08-07 |
EP3411410B1 (en) | 2021-03-10 |
DK3411410T3 (en) | 2021-06-07 |
US20190040149A1 (en) | 2019-02-07 |
JP6533630B2 (en) | 2019-06-19 |
ES2876407T3 (en) | 2021-11-12 |
US10913801B2 (en) | 2021-02-09 |
JP2019512017A (en) | 2019-05-09 |
WO2017132827A1 (en) | 2017-08-10 |
CN108779177A (en) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10913801B2 (en) | PD-1 antibodies | |
EP3334824B1 (en) | Pd-1 antibodies | |
AU2016426507B2 (en) | PD-1 antibodies | |
JP6518005B2 (en) | PD-L1 antibody | |
JP2018531219A6 (en) | PD-L1 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17746860 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018558472 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017746860 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017746860 Country of ref document: EP Effective date: 20180903 |